摘要
目的探究英夫利西单克隆抗体治疗后类风湿关节炎患者血脂水平的变化。方法选择2015年5月至2016年5月本院收治的类风湿关节炎患者43例,随机分为对照组(21例)和观察组(22例),对照组给予常规抗类风湿治疗,观察组给予英夫利西单克隆抗体治疗。治疗6个月后,对比两组患者的体征缓解情况、实验室指标变化、血脂水平变化以及不良反应(过敏、皮疹、嘴唇发麻)发生率。结果治疗后观察组患者的体征缓解情况、实验室指标变化及血脂水平变化明显优于对照组,不良反应发生概率(13.64%)明显低于对照组(42.86%),差异有显著性(P<0.05)。结论英夫利西单克隆抗体治疗能够明显改善类风湿关节炎患者的体征、实验室指标和血脂水平,值得在临床中推广应用。
Objective The change of blood lipid level of Xidan infliximab polyclonal antibody therapy in rheumatoid arthritis. Method 43 patients with rheumatoid arthritis were selected from May 2015 to May 2016 in our hospital. The patients were randomly divided into control group（21 cases） and observation group（22 cases）, the control group using conventional treatment of anti-rheumatoid, the observation group were treated with Xidan infliximab polyclonal antibody. After 6 months of treatment, compared two groups of patients with signs of relief, changes in laboratory index, changes in blood lipid levels and adverse reaction probability（allergy, skin rash, numb lips）. Result The observation group of patients with signs of relief, changes in laboratory index, changes in blood lipid levels and adverse reaction probability（13.64%） was significantly better than the control group of patients with signs of relief, changes, changes in blood lipid levels and adverse reaction probability（42.86%）, statistically significant differences between two groups of data exist（P〈0.05）. Conclusion Xidan infliximab polyclonal antibody can effectively improve signs, laboratory indexes, blood lipid levels in rheumatoid arthritis, is worthy of promotion and application.
作者
李晓燕
张惠琴
李辉
张艳
LI Xiao-yan;ZHANG Hui-qin;LI Hui;ZHANG Yan(Department of Endocrinology, Shaanxi Provincial People＇s Hospital, Shaanxi Xi ＂an 710068, China;Department of Medicine, Shaanxi Provincial People＇s Hospital, Shaanxi Xi ＇an 710068, China)
出处
《中国医刊》
CAS
2017年第12期42-44,共3页
Chinese Journal of Medicine
基金
陕西省自然科学基金(2016JQ8055)
关键词
类风湿关节炎
英夫利西单克隆抗体
血脂
Rheumatoid arthritis
Xidan infliximab polyelonal antibody
Serum lipid levels
